» Articles » PMID: 33678236

Treatment Approaches for Women with Positive Cervical Screening Results in Low-and Middle-income Countries

Overview
Journal Prev Med
Specialty Public Health
Date 2021 Mar 8
PMID 33678236
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The primary goal of cervical screening is to identify women with cervical precancers who need treatment to prevent invasive cervical cancer. Cervical cancer screening programs in high-resource settings rely on a multi-step process to reassure the majority of women of low cancer risk and treat the small number of women at high risk of precancer and cancer. The requirement of major resource investment for training and capacity building of multi-step cervical cancer screening programs prevents their introduction in low- and middle-income countries (LMICs). Screen-and-treat programs have been evaluated and introduced in some countries that use mainly ablative treatment as primary treatment options. Ablative treatment with cryotherapy and thermal ablation has a favorable tradeoff of benefits and harms and can be introduced more widely than excisional treatment in LMICs. While most women below 40 are eligible for ablative procedures, fewer than 50% are eligible by age 50 and ablative treatment is not appropriate over age 50. Excisional treatment is required for women ineligible for ablative treatment. Since screening programs in LMICs necessarily detect invasive cancers, cancer treatment and palliative care needs to be considered as well.

Citing Articles

CerviFusionNet: A multi-modal, hybrid CNN-transformer-GRU model for enhanced cervical lesion multi-classification.

Sha Y, Zhang Q, Zhai X, Hou M, Lu J, Meng W iScience. 2024; 27(12):111313.

PMID: 39634563 PMC: 11615576. DOI: 10.1016/j.isci.2024.111313.


Expanding management strategies for cervical precancerous lesions in resource-limited settings: insights from a training center in a district hospital in Ghana.

Effah K, Tekpor E, Wormenor C, Bosoka S, Afetor M, Dugbazah A BMC Womens Health. 2024; 24(1):428.

PMID: 39060995 PMC: 11282615. DOI: 10.1186/s12905-024-03263-0.


Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.

Jain M, Yadav D, Jarouliya U, Chavda V, Yadav A, Chaurasia B Pathogens. 2023; 12(12).

PMID: 38133265 PMC: 10745624. DOI: 10.3390/pathogens12121380.


Optimised feature selection-driven convolutional neural network using gray level co-occurrence matrix for detection of cervical cancer.

Sudhakar K, Saravanan D, Hariharan G, Sanaj M, Kumar S, Shaik M Open Life Sci. 2023; 18(1):20220770.

PMID: 38045489 PMC: 10693012. DOI: 10.1515/biol-2022-0770.


Cervical Cancer Screening and Treatment Algorithms Using Human Papillomavirus Testing-Lessons Learnt from a South African Pilot Randomized Controlled Trial.

Sebitloane H, Forestier M, Ginindza T, Dhlomo W, Moodley-Govender E, Darragh T Cancer Epidemiol Biomarkers Prev. 2023; 33(6):779-787.

PMID: 37955560 PMC: 11145165. DOI: 10.1158/1055-9965.EPI-23-0752.